Residents and Fellows Research in Progress
Tuesday, November 14, 2023
08:30 AM–10:00 AM
Abstract
Introduction: Patients undergoing surgery receive medications for post-operative pain control that are impacted by pharmacogenetic (PGx) variants including nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. However, PGx testing is not routinely performed.
Research Question or Hypothesis: Assessing knowledge and attitudes towards PGx testing will identify barriers to clinical implementation.
Study Design: Survey of obstetrics/gynecology (OB/Gyn) physicians who are participating in a prospective, randomized, pilot implementation trial of preemptive PGx testing.
Methods: An 18-question REDCap® survey consisting of multi-select, single-select, yes/no, free text, and 5-point Likert scale questions was sent to physicians. The survey instrument was designed/adapted from previous studies. Survey distribution launched in October 2022 and will continue until October 2023. Descriptive statistics are used to summarize results.
Results: To date, 55 surveys have been distributed, resulting in 37 (67%) respondents. Most respondents are female (84%) and trainees in OB/Gyn (65%). Most (84%) have heard of PGx, but none have ordered a test. Only 14% agree/strongly agree in their ability to utilize PGx results and almost all (95%) agree/strongly agree that it would be beneficial to consult a pharmacist for genotype-guided medication recommendations. The majority (81%) agree/strongly agree that PGx testing can improve patient care. Commonly identified barriers are shown in Table 1. Respondents preferred PGx training methods include grand rounds and training in residency.
Conclusion: Ob/Gyn physicians have limited knowledge and experience with PGx testing. Results will be utilized to develop implementation strategies and educational initiatives for post-operative pain management.
| Table 1. Top Barriers to PGx testing |
| Barriers* |
n (%) |
| Little training |
34 (92) |
| Lack of PGx in society guidelines |
21 (57) |
| Access to PGx laboratory |
21 (57) |
| Access to PGx specialists |
20 (54) |
| *Can select more than one |
Presenting Author
Glenda Hoffecker Pharm.D.University of Pennsylvania
Authors
Stefan Gysler M.D., MHS
University of Pennsylvania
Lakeisha Mulugeta-Gordon M.D.
Hospital of the University of Pennsylvania
Mary Deagostino-Kelly M.D., MPH
Penn Medicine
Sony Tuteja Pharm.D., MS
University of Pennsylvania
Victoria Wittner MPH
University of Pennsylvania